InClinica Chief Medical Officer Educates Boston University Students on Drug Development
Edward Brennan to present lecture on the drug development process at Boston University School of Medicine
PHILADELPHIA (December 7, 2016) – Edward Brennan, Chief Medical Officer of InClinica, Inc. ‒ a global, clinical CRO ‒ will present a lecture to Boston University Master of Public Health and Pharmaceutical students on Wednesday, December 7 in Boston, Massachusetts.
Brennan’s presentation will explore modern-day drug development, including how the process now is different than in the past, and how it will continue to evolve in the future. He will also address the changing role of CROs in the pharmaceutical arena, as well as how clinical trials are expanding on a global scale.
“The drug development process is constantly changing,” said Brennan. “It’s important to educate students on the challenges and opportunities that exist, to continue working toward a smoother and more efficient process that affords patients easier access to essential treatments. Today’s students will shape tomorrow’s industry.”
Brennan’s lecture will begin at 5 p.m. EST at the Boston University Medical School.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.